rTMS for MDD: 5.5cm Rule vs. F3 Targeting

NACompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

September 13, 2022

Study Completion Date

September 13, 2022

Conditions
Major Depressive DisorderDepression
Interventions
DEVICE

Repetitive transcranial magnetic stimulation

Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.

Trial Locations (1)

52242

University of Iowa Hospitals & Clinics, Iowa City

All Listed Sponsors
lead

Nicholas Trapp

OTHER

NCT03378570 - rTMS for MDD: 5.5cm Rule vs. F3 Targeting | Biotech Hunter | Biotech Hunter